

TABLE 1: Patient Characteristics and Summary of COVID-19 Vaccination or Infection-induced TTP Course

Patient	Age (years)	Sex	Medical history	Vaccine status	Prior COVID infection	TTP symptoms	Treatment	Treatment Side Effects	Current clinical status
1	19	F	TTP	Pfizer-BioNTech mRNA vaccine dose 1	Not reported; SARS-CoV-2 PCR not detected at time of relapse	Bruising, hematuria	TPE x 4 days Methylprednisolone, rituximab, caplacizumab	None to-date	In remission
2	15	F	Arrhythmia of unknown etiology, previously on metoprolol	Pfizer-BioNTech mRNA vaccine dose 1	Not reported; SARS-CoV-2 Anti-Spike IgM positive after vaccination	Fatigue, bruising	TPE x 4 days, Methylprednisolone, rituximab, FFP infusion	Herpes zoster infection, weight gain	In remission
3	17	F	Asthma, NAFLD	Unvaccinated	No clinical history; SARS-CoV-2 IgG antibodies positive on presentation	Hemiparesis, headache, fatigue, jaundice, hematuria	TPE x 5 days, rituximab, caplacizumab	Steroid induced hyperglycemia requiring insulin, extremity tremors	In remission
4	17	M	ASD/VSD repaired; precocious puberty treated with hormone suppression	Unvaccinated	3 weeks prior to presentation with symptomatic infection; COVID antibodies negative ~3 months after initial presentation	Initial hematuria; representation with jaundice, pallor, neurologic abnormalities; refractory	TPE x 5 days, rituximab, prednisone, cyclosporine, caplacizumab, FFP infusion	Hypertension during steroid course	Receiving Koate-DVI infusions biweekly

TTP=thrombotic thrombocytopenic purpura
TPE=therapeutic plasma exchange
FFP=fresh frozen plasma
NAFLD= nonalcoholic fatty liver disease
ASD=atrial septal defect
VSD=ventricular septal defect